Research Progress in Prevention and Treatment of Biological Agents for Oral Mucositis Caused by Hematopoietic Stem Cell Transplantation

doi:10.13701/j.cnki.kqyxyj.2023.07.004

Abstract

Abstract: Hematopoietic stem cell transplantation (HSCT) is one of the most important treatment modalities for hematologic malignancies, but this treatment often causes oral mucositis (OM). The incidence of OM caused by HSCT (HSCT-OM) is high and the clinical treatment is difficult. Many biologic agents have been used exploratively in the treatment of HSCT-OM and some are effective. This paper reviews the clinical studies of biologic agents, and provides a reference for the clinical prevention and treatment of HSCT-OM.

Key words: hematopoietic stem cell transplantation, oral mucositis, biological agents

GUO Jincai, ZHANG Shusheng. Research Progress in Prevention and Treatment of Biological Agents for Oral Mucositis Caused by Hematopoietic Stem Cell Transplantation[J]. Journal of Oral Science Research, 2023, 39(7): 582-585.

References

[1] Chaudhry HM, Bruce AJ, Wolf RC, et al. The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: A systematic review [J]. Biol Blood Marrow Transplant, 2016, 22(4):605-616.
[2] da Silva BM, Prosdócimo ML, Gasparini LR, et al. Most used photobiomodulation dosimetry parameters to treat oral mucositis after preconditioning for hematopoietic stem cell transplantation: systematic review and meta-analysis [J]. Support Care Cancer, 2022, 30(5):3721-3732.
[3] Costa ALF, Santos BA, Torregrossa VR, et al. Oral shedding of CMV and HSV-1 in hematopoietic stem cell transplantation patients [J]. Oral Dis, 2021, 27(6):1572-1579.
[4] Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers [J]. N Engl J Med, 2004, 351(25):2590-2598.
[5] Coutsouvelis J, Corallo C, Spencer A, et al. A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancy [J]. Crit Rev Oncol Hematol, 2022, 172:103606.
[6] Raber-Durlacher JE, Von Bültzingslöwen I, Logan RM, et al. Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients [J]. Support Care Cancer, 2013, 21(1):343-355.
[7] Stiff PJ, Leinonen M, Kullenberg T, et al. Long-term safety outcomes in patients with hematological malignancies undergoing autologous hematopoietic stem cell transplantation treated with palifermin to prevent oral mucositis [J]. Biol Blood Marrow Transplant, 2016, 22(1):164-169.
[8] Elting LS, Shih YC, Stiff PJ, et al. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results [J]. Biol Blood Marrow Transplant, 2007, 13(7):806-813.
[9] Logan RM, Al-Azri AR, Bossi P, et al. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines [J]. Support Care Cancer, 2020, 28(5):2485-2498.
[10] Patel P, Robinson PD, Baggott C, et al. Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update [J]. Eur J Cancer, 2021, 154:92-101.
[11] Alqahtani SS, Khan SD. Management of oral mucositis in children [J]. Eur Rev Med Pharmacol Sci, 2022, 26(5):1648-1657.
[12] Dazzi C, Cariello A, Giovanis P, et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study [J]. Ann Oncol, 2003, 14(4):559-563.
[13] Van der Lelie H, Thomas BL, Van Oers RH, et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study [J]. Ann Hematol, 2001, 80(3):150-154.
[14] Gordon B, Spadinger A, Hodges E, et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation [J]. J Clin Oncol, 1994, 12(9):1917-1922.
[15] Kim KI, Kim JW, Lee HJ, et al. Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation [J]. Am J Hematol, 2013, 88(2):107-112.
[16] Kim JW, Kim MG, Lee HJ, et al. Topical recombinant human epidermal growth factor for oral mucositis induced by intensive chemotherapy with hematopoietic stem cell transplantation: Final analysis of a randomized, double-blind, placebo-controlled, phase 2 trial [J]. PLoS One, 2017, 12(1):e0168854.
[17] Berglund S, Watz E, Remberger M, et al. Granulocyte transfusions could benefit patients with severe oral mucositis after allogeneic hematopoietic stem cell transplantation [J]. Vox Sang, 2019, 114(7):769-777.
[18] Piccin A, Rebulla P, Pupella S, et al. Impressive tissue regeneration of severe oral mucositis post stem cell transplantation using cord blood platelet gel [J]. Transfusion, 2017, 57(9):2220-2224.
[19] Ruggiero T, Pol R, Camisassa D, et al. Use of sodium hyaluronate and synthetic amino acid precursors of collagen for the symptomatic treatment of mucositis in patients undergoing haematopoietic stem cell transplants [J]. J Biol Regul Homeost Agents, 2016, 30(3):889-894.
[20] Ruggiero T, Pol R, Camisassa D, et al. Treatment of symptomatic oral mucositis with sodium hyaluronate and synthetic amino acid precursors of collagen in patients undergoing haematopoietic stem cell transplantation [J]. J Biol Regul Homeost Agents, 2018, 32(3):737-743.
[21] Giles FJ, Rodriguez R, Weisdorf D, et al. A phase Ⅲ, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy [J]. Leuk Res, 2004, 28(6):559-565.
[22] Hosseinjani H, Hadjibabaie M, Gholami K, et al. The efficacy of erythropoietin mouthwash in prevention of oral mucositis in patients undergoing autologous hematopoietic SCT: a double-blind, randomized, placebo-controlled trial [J]. Hematol Oncol, 2017, 35(1):106-112.
[23] Ohbayashi Y, Imataki O, Uemura M, et al. Oral microorganisms and bloodstream infection in allogeneic hematopoietic stem cell transplantation [J]. Clin Oral Investig, 2021, 25(7):4359-4367.
[24] Elting LS, Chang YC. Costs of oral complications of cancer therapies: Estimates and a blueprint for future study [J]. J Natl Cancer Inst Monogr, 2019, 2019(53):lgz010.
[25] Shouval R, Kouniavski E, Fein J, et al. Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation [J].Eur J Haematol, 2019, 103(4):402-409.
[26] Curra M, Baldin J. Investigation of oral and general health status and IL-1β gene polymorphism as risk factors for oral mucositis in hematopoietic stem cell transplantation patients [J]. Braz Oral Res, 2022, 36:e016.
[27] Sung L, Robinson P, Treister N, et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation [J]. BMJ Support Palliat Care, 2017, 7(1):7-16.